TSE:TR Trillium Therapeutics (TR) Stock Price, News & Analysis → If you have $2,500 bucks… check this out (From DTI) (Ad) Free TR Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,075 shsAverage Volume99,071 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Trillium Therapeutics alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Trillium Therapeutics Stock (TSE:TR)Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.Read More Ad DTIWhat is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. TR Stock News HeadlinesApril 15, 2024 | finance.yahoo.comSezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura BioApril 2, 2024 | finance.yahoo.comUpstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership TeamApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 12, 2024 | finance.yahoo.comRatio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted RadiopharmaceuticalsJanuary 17, 2024 | bizjournals.comRatio Therapeutics raises $50M for tumor-targeting radiopharmaceuticalsJune 22, 2023 | finance.yahoo.comTvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 InhibitorJune 20, 2023 | benzinga.comPD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsightMay 9, 2023 | finance.yahoo.comRatio Therapeutics Announces Opening of New Research and Development FacilityApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 25, 2023 | finance.yahoo.comTrillium Engineering Announces Its Latest Innovation in Cameras Utilizing AI Technology - HD80-AIMMarch 10, 2023 | msn.comWho's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In PersonFebruary 6, 2023 | finanznachrichten.deViridian Therapeutics, Inc: Viridian Appoints Scott Myers as President and Chief Executive OfficerJanuary 28, 2023 | detroitnews.comTaylor Trillium building into Division 4 state power, behind coach Terrell GeorgeDecember 19, 2022 | benzinga.comLeiomyosarcoma Drug Pipeline Research Report 2022: Comprehensive Insights on 18+ Companies and 18+ Pipeline DrugsDecember 6, 2022 | finance.yahoo.comRatio Therapeutics Appoints Reed Malleck as Chief Financial OfficerNovember 3, 2022 | seekingalpha.comPfizer: Q3 Earnings Review - Planning For Life After COVIDAugust 8, 2022 | msn.comCash-rich Pfizer snaps up Global Blood Therapeutics for $5.4 billionMay 22, 2022 | seekingalpha.comPfizer: Management's M&A Activity Is Winning Me OverMay 18, 2022 | finanznachrichten.deThiogenesis Therapeutics, Corp.: Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102May 18, 2022 | stockhouse.comThiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102May 14, 2022 | msn.com3 Dirt-Cheap Stocks You Can Buy Right NowMay 10, 2022 | baystreet.caPfizer Buys Biohaven for $11.6BFebruary 17, 2022 | morningstar.comNeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioJanuary 25, 2022 | yahoo.com$51,300 OTF Grant helped breast cancer patients in Ontario access educational resources during the pandemicJanuary 12, 2022 | finance.yahoo.comTCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy OfficerDecember 20, 2021 | apnews.comSensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent DirectorNovember 17, 2021 | law360.comPfizer's $2.3B Trillium Deal Closes Without FTC ChallengeSee More Headlines Receive TR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolTSE:TR CUSIPN/A CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesCalvin R. Stiller M.D.Independent Chairman of the BoardNiclas StiernholmPresident, Chief Executive Officer, DirectorJames T. ParsonsChief Financial OfficerMalik SlassiSenior Vice President - Discovery ResearchRobert UgerChief Scientific OfficerScott DuncanDirector of Intellectual PropertyPenka PetrovaChief Development OfficerEric L SieversChief Medical OfficerLuke M. Beshar CPA (Age 59)Independent Director Henry Friesen M.D. (Age 79)Independent Director More Executives TR Stock Analysis - Frequently Asked Questions Is Trillium Therapeutics a good dividend stock? Trillium Therapeutics (TSE:TR) pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), ConocoPhillips (COP), Canadian Natural Resources (CNQ), bluebird bio (BLUE) and Biogen (BIIB). How do I buy shares of Trillium Therapeutics? Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
